Axsome Therapeutics Inc. (AXSM)
NASDAQ: AXSM · Pharmaceutical Preparations · New York, NY
Our rating: Positive
Call changed from Cautious to Positive at $139.61, moderate conviction, November 3, 2026.
Breaks if: The Positive view is undermined if revenue growth decelerates below 30% year-over-year in either of the next two quarterly reporting periods, or if trailing twelve-month free cash outflow widens beyond $150M — either outcome would signal that commercial scaling is faltering and the 11.5× revenue multiple cannot be sustained. A drawdown of 35% from the current price without a corresponding deterioration in reported fundamentals would also prompt a full reassessment, as it would suggest the market is pricing in impairment this call does not yet capture.
Key figures
| Market value | $6.8B |
|---|---|
| Revenue, last 12 months | $865M |
| Net income, last 12 months | −$157M |
| Free cash flow, last 12 months | −$83M |
| Price to earnings | n/a |
| Free cash flow yield | −1.2% |
| Dividend yield | 0.0% |
| Operating margin | −17.5% |
| Return on equity | −175.6% |
| Beta to the S&P 500 | 0.69 |
| Volatility, annualized | 43.4% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $260M | 51.9% | $-0.25 | −$10M |
| June 30, 2026 | $218M | 45.5% | $-0.99 | −$33M |
| March 31, 2026 | $191M | 57.4% | $-1.26 | −$21M |
| December 31, 2025 | $196M | 65.0% | $-0.55 | −$19M |
| September 30, 2025 | $171M | 63.2% | $-0.94 | $988000.00 |
| June 30, 2025 | $150M | 72.1% | $-0.97 | −$32M |
| March 31, 2025 | $121M | 62.0% | $-1.22 | −$44M |
| December 31, 2024 | $119M | 66.0% | $-1.54 | −$26M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.30B: Claude 72%, Gemini 90%, Mistral 65%
- Diluted earnings per share are above zero: Claude 12%, Gemini 5%, Mistral 30%
- Free cash flow for the quarter is above zero: Claude 35%, Gemini 40%, Mistral 35%
15 ledger entries and 35 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.